運営者情報（About the Publisher）
GeneLumen（ジーンルーメン）は、LRRK2・GBA・BRCA・APOEなどの遺伝子と疾患リスクの関係を、査読済みの研究データにもとづいて「運命ではなく確率」として解説する、日英バイリンガルの医療情報メディアです。運営はGeneLumen編集部。公開された医学エビデンス（tier 1〜2）を横断分析・再構成する集約者（アグリゲーター）として運営しています。
編集責任者
水野 悠（Yu Mizuno） ｜ 編集責任者 / 医療・ゲノム情報エディター（非医師）
分子生物学のバックグラウンドを持つ医療・ゲノム情報エディター。査読済み論文・NIH（MedlinePlus / GeneReviews）・難病情報センター（厚生労働省）・各学会ガイドラインなどの一次情報を横断し、一般読者向けに要約・再構成しています。医師・臨床遺伝専門医ではありません。記事は教育目的の情報提供であり、診断・治療を行うものではありません。検査の要否や治療方針の判断は、必ず主治医・臨床遺伝専門医・認定遺伝カウンセラーにご相談ください。緊急時は119へ。
主に参照している一次情報源
- MedlinePlus Genetics（NIH / 米国国立医学図書館）
- GeneReviews（NCBI / ワシントン大学）
- PubMed（NIH / 査読論文データベース）
- 難病情報センター（厚生労働省 / AMED 委託事業）
- 日本人類遺伝学会
This page describes the editorial policy and operational standards of genelumen.
1. Research-First Editorial Policy
genelumen is built on a single editorial principle: medical and genetic-disease content should be designed from research evidence, not anecdote. The internet is full of personal experience reports, marketing material, and intuitive advice. We do not produce any of those.
Every article on this site follows these rules:
- Cite at least five (5) sources from peer-reviewed literature, government health agencies, or academic / research institutions (tier 1-2 sources).
- Use research framing (“A 2024 Nature Medicine study found…”, “The 2024 Lancet Commission estimates…”) in the opening summary and at the head of each major section.
- List every cited source URL in the References section at the end of each article.
We do not publish “I tried X and felt better” testimonials, miracle-cure narratives, or supplement marketing copy. Our aim is reproducible understanding built on the published evidence base.
2. Aggregator Position
genelumen does not offer original medical opinions or personal clinical experience. We are aggregators: we read across the published evidence and reorganize it for general readers. Every article footer carries the following type of disclosure:
Author: genelumen editorial team. This article aggregates N sources from peer-reviewed medical literature and public health agencies (tier 1=A / tier 2=B).
By offering aggregation rather than opinion, we help readers acquire a map of the research quickly, while keeping clinical judgment where it belongs — with qualified clinicians.
3. Source Tier Classification
| Tier | Type | Examples |
|---|---|---|
| tier 1 | Primary research, government health agencies, official clinical guidelines | Peer-reviewed journals (Nature Medicine, NEJM, JAMA, Lancet); NIH/NIA/CDC/FDA; Health Canada; ACMG / NSGC clinical guidelines |
| tier 2 | Systematic reviews, meta-analyses, academic textbooks | Cochrane Reviews; review articles in clinical journals; established medical-genetics textbooks |
| tier 3 | Secondary explanations, patient education resources | Major medical foundations’ patient-facing pages, MedlinePlus, university hospital explainer pages |
| tier 4 | Personal blogs, testimonials, marketing material | Not used as primary evidence |
Each article cites at least five tier 1+2 sources as a hard rule. Tier 3 is used only as supporting context. Tier 4 is excluded.
4. Dialogue Style
At the opening of each article and beneath each major section we insert short dialogues between two characters:
- Ken — a 30-something man worried about family history, voicing the reader’s questions and anxieties.
- The Geneticist — a board-certified medical geneticist character who responds with what published research actually shows.
This is a presentation device. The Geneticist character is not a real, identified clinician and the dialogues do not constitute clinical advice. The format exists to make research-dense articles approachable; the underlying citations carry the authority.
5. Transparency Policy
We treat research-source disclosure as our primary transparency signal:
- References section is mandatory on every article, listing ~10 source URLs with publication identifiers.
- Aggregation count is disclosed in each footer (“aggregates N sources, tier 1=A / tier 2=B”).
- Last updated date is explicit on every article and refreshed when content is revised.
We do not label articles as “AI-assisted.” Google’s Quality Rater Guidelines do not require such labels (the standard is content quality, not authorship method), and labels of that kind have been shown to reduce share-through on social platforms and source weight in LLM citations. The substantive transparency obligation — disclosing source evidence — is fully met.
6. Update Policy
- New articles: published as research surveys are completed for each topic.
- Existing article revisions: when cited research is superseded or new evidence emerges, articles are updated in place and the last-updated date is refreshed.
- Corrections: when factual errors are identified, we verify against the primary literature and correct promptly.
7. Intended Readers
- Adults concerned about a family history of a specific genetic condition (Alzheimer’s, hereditary cancer syndromes, inherited metabolic disorders, etc.).
- Individuals who have received direct-to-consumer (DTC) genetic test results and want a research-grounded view of what those results mean.
- Family members supporting a loved one through a new diagnosis who need a calm overview of the published evidence.
- Healthcare-adjacent professionals (nurses, pharmacists, social workers) who want a fast aggregation of recent research on a specific gene or condition.
8. Medical Disclaimer
This site is for educational purposes only. It is not a substitute for advice, diagnosis, or treatment from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, interpretation, treatment, family disclosure, or care, consult a qualified clinician. In emergencies, call 911 (US/Canada), 999 (UK), or 119 (Japan).
9. Contact
For feedback, error reports, corrections, or media inquiries, please use the contact form.
Established: June 17, 2026
Last revised: June 17, 2026